Monday, September 19, 2016

BRIEF-FDA approves 6-month primary end point for the Lutonix

* Approves 6 Primary efficacy end point in clinical trial is

a composite of limb salvage and primary patency at 6 months

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)